News Details

ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with AvastinĀ® in Recurrent Ovarian Cancer, Regardless of Platinum Status

About ImmunoGen, Inc.

Price Chart